Abstract
Patients with uncontrolled, moderate-to-severe asthma have higher risk for exacerbations and impaired lung function. Dupilumab is an antibody that blocks interleukin (IL)-4 and IL-13. We aimed to characterize patients with asthma initiating dupilumab, enrolled in the RAPID registry (NCT04287621).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
